Agilent Stock Performance & Valuation Analysis 2026 | Business Review - News and Statistics

FierceBiotechIMU Biosciences nabs $53M funding round to ‘decode’ the immune system

FierceBiotechAscidian, Lilly ink RNA exon editing pact worth up to $1.9B for genetic kidney diseases

Endpoints NewsLilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases

BioPharma DiveLilly, Ascidian link up in RNA exon editing pact

CellPlant cell wall-plasma membrane attachments mediate stress resilience through cellulose synthase complexes and remorins

CellExplosive cytotoxicity of ruptoblasts bridges hormone surveillance and immune defense

LabiotechSurge in M&As driven by patent expirations

Thermo FisherThermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate Drug Discovery - BioSpectrum Asia

eLifeHSD17B7 is required for the function of sensory hair cells by regulating cholesterol synthesis

BioPharma DiveCelcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial

Clinical OMICsAI-Powered Blood Test Detects Early Retinal Damage in Diabetes

Clinical OMICsMature Intestinal Cells Revert to Stem-Like State to Sustain Colorectal Cancer